This is why your clinician will start you on a very low dose and increase it gradually, which gives your body time to adjust
The SUSTAIN-6 Trial (Once-Weekly Semaglutide) The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) consisted of 3297 people living with T2DM, 83% with established cardiovascular disease, receiving once-weekly semaglutide (0.5 and 1.0 mg) or placebo
Table of Contents: What is hyperhidrosis treatment
It creates misaligned incentives in the market where more expensive drugs are preferred over less expensive medicines, which is not intuitive because at the end of the day, the whole purpose of having an insurer, insurance card or a pharmacy benefit manager overlooking your insurance, your pharmacy benefits, is to cover the less expensive medicines first
Diabetes Obes Metab 2014
Site reactions are typically not an indication to discontinue the drug